Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer CEO McKinnell Says OTCs Still Provide Value

This article was originally published in The Tan Sheet

Executive Summary

Consumer healthcare products remain key to Pfizer's strategic plan, Chairman & CEO Hank McKinnell maintained during a speech at the National Press Club May 17

You may also be interested in...



Pfizer Consumer Business Not Critical During “Transition” Year

Pfizer does not consider its consumer business to be key to the company's strategic outlook during the 2005 "transition" year, CEO Hank McKinnell indicated during an April 5 business review with analysts

FDA Determines A “Class Effect” Is In Play For All NSAIDs

An FDA decision to request revised safety labeling changes to OTC NSAIDs enables manufacturers to continue positioning the drugs as safer alternatives to their prescription counterparts, which will carry "black box" warnings going forward

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel